Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual

XR-NTX did not significantly increase rates of healthcare utilization compared to TAU. Provider concerns regarding healthcare utilization should not preclude the consideration of XR-NTX as therapy for opioid use disorders.